anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Although adequate physical activity has been shown to be beneficial in early breast cancer, evidence in metastatic breast cancer is sparse and contradictory, which could be related to distinct effects of physical activity on the different molecular cancer subtypes. Therefore, we here evaluated the effect of physical activity on progression-free and overall survival (PFS, OS) in metastatic breast cancer, specifically looking at molecular subtypes.
METHODS: International Physical Activity Questionnaire (IPAQ) questionnaires, filled out by patients enrolled in the prospective PRAEGNANT registry (NCT02338167; n = 1,270) were used to calculate metabolic equivalent task (MET) minutes, which were subsequently categorized into low (n = 138), moderate (n = 995) or high IPAQ categories (n = 137). Cox regression analyses were used to evaluate the impact of IPAQ categories and its interaction with molecular subtypes on PFS and OS.
RESULTS: Patient and tumor characteristics were equally distributed across IPAQ categories. HER2pos, HRpos and TNBC were present in 23.1%, 65.7% and 11.2% of patients, respectively. IPAQ scores did not have an impact on PFS and OS in addition to established prognostic factors, either overall or in particular molecular subtypes (PFS: p = 0.33 and OS: p = 0.08, likelihood ratio test). Exploratory analyses showed higher overall survival rates for high IPAQ categories compared to low/moderate IPAQ categories in luminal B-like breast cancer.
CONCLUSIONS: Self-reported physical activity using the IPAQ questionnaire did not significantly affect PFS or OS in patients suffering from metastatic breast cancer. Nevertheless, some hypothesis-generating differences between molecular subtypes could be observed, which may be interesting to evaluate further.
INTRODUCTION: Ketorolac is a frequently used anesthetic pain agent which is traditionally avoided during tonsillectomy due to concern for postoperative hemorrhage. Our goal was to assess the degree of risk associated with the use of Ketorolac following pediatric tonsillectomy.
METHODS: The TriNetX electronic health records research database was queried in January 2024 for patients undergoing tonsillectomy with or without adenoidectomy under the age of 18 years and without a diagnosed bleeding disorder. Patients were separated into two cohorts either having received or not having received ketorolac the same day as surgery. Propensity score matching was performed for age at the time of surgery, sex, race, ethnicity, and preoperative diagnoses. The outcomes assessed were postoperative hemorrhage requiring operative control within the first day (primary hemorrhage) and within the first month after surgery (secondary hemorrhage).
RESULTS: 17,434 patients were identified who had undergone pediatric tonsillectomy with or without adenoidectomy and had received ketorolac the same day as surgery. 290,373 patients were identified who had undergone pediatric tonsillectomy with or without adenoidectomy and had not received ketorolac the same day as surgery. 1:1 propensity score matching resulted in 17,434 patients within each cohort. Receipt of ketorolac the same day as surgery resulted in an increased risk of primary hemorrhage OR 2.158 (95 % CI 1.354, 3.437) and secondary hemorrhage OR 1.374 (95 % CI 1.057, 1.787) requiring operative control.
CONCLUSION: Ketorolac use during pediatric tonsillectomy with or without adenoidectomy was associated with an increased risk of postoperative primary and secondary bleeding requiring surgery.
There is substantial evidence that rIL-2 increases CD4+ cell count. Whether or not rIL-2 delays progression to AIDS and extends survival is currently unknown, such clinical benefits of rIL-2 can only be established in a large, long-term, randomized trial. This study examines the effect of two different rIL-2 doses on HIV viral burden and CD4+ cell count and provides additional information on optimal dosing, safety, and antiviral activity of rIL-2.

Patients are randomized to receive one of two subcutaneous (sc) doses of recombinant rIL-2 or no rIL-2. Those patients who take rIL-2 initially receive three courses of treatment. For this study, a course is defined as eight calendar weeks, including the five-day period of sc rIL-2 administration. Additional courses are given (no more frequently than every 6 weeks) in order to maintain a CD4+ count of at least twice its baseline level or at least 1,000 cells/mm3. Follow-up will continue for all patients until a common closing date of 12 months following enrollment of the last patient.
Participants performed 9 sessions of HIIT over 3 weeks, utilizing progressive overload by increasing the number of bouts by 1 each week. They started with 8 bouts on week 1, 9 bouts on week 2, and 10 bouts on week 3.
The invention provides an anti-TIGIT monoclonal antibody and application thereof, wherein the anti-TIGIT monoclonal antibody comprises a heavy chain variable region and a light chain variable region; the heavy chain variable region comprises a heavy chain CDR1 shown in SEQ ID NO. 1, a heavy chain CDR2 shown in SEQ ID NO. 2 and a heavy chain CDR3 shown in SEQ ID NO. 3; the light chain variable region includes light chain CDR1 shown in SEQ ID NO. 4, light chain CDR2 shown in SEQ ID NO. 5 and light chain CDR3 shown in SEQ ID NO. 6. The anti-TIGIT monoclonal antibody has strong specific recognition binding capacity to antigen TIGIT, can effectively block the binding of the TIGIT and a ligand CD155 thereof, and has wide application prospect.
The invention relates to a porcine parvnvirus living vaccine and a preparation method thereof. The living vaccine is prepared by adopting a PPVS-1A strain (the HA valence is not less than 29, and the TCID50 is not less than 107.0/ml) to obtain a cell culture through being inoculated with a swine testis (ST) subculture cell growing well, adding a suitable stabilizing agent and carrying out freezing vacuum drying. The virus content of each first part of the living vaccine is not less than 105.0TCID50. Compared with the prior art, the porcine parvnvirus living vaccine has good immunogenicity, rapid antibody generation after immunization, high titer and long maintenance time of the generated antibody, long retention period and small immunizing dose. When the porcine parvnvirus living vaccine is used to carry out vaccine injection a plurality of weeks before hybridization, the pregnant sow can maintain strong immunizing power in the easy infection period. The porcine parvnvirus living vaccine is the excellent choice for preventing the porcine parvnvirus. The adopted preparation method has reasonable process and lower cost and greatly reduces the cost burden of the livestock breeding.
Protein drugs have been widely used in treating various clinical diseases because of their high specificity, fewer side effects, and favorable therapeutic effect, but they greatly suffer from their weak permeability through tissue barriers, high sensitivity to microenvironments, degradation by proteases, and rapid clearance by the immune system. Herein, we disrupted the standard protocol where protein drugs must be delivered as the cargo via a delivery system and innovatively developed a free entrapping matrix strategy by simply mixing bevacizumab (Beva) with zinc ions to generate Beva-NPs (Beva-Zn2+), where Beva is coordinatively cross-linked by zinc ions with a loading efficiency as high as 99.2% ± 0.41%. This strategy was universal to generating various protein NPs, with different metal ions (Cu2+, Fe3+, Mg2+, Sr2+). The synthetic conditions of Beva-NPs were optimized, and the generated mechanism was investigated in detail. The entrapment, releasing profile, and the bioactivities of released Beva were thoroughly studied. By using in situ doping of the fourth-generation polyamindoamine dendrimer (G4), the Beva-G4-NPs exhibited extended ocular retention and penetration through biobarriers in the anterior segment through transcellular and paracellular pathways, effectively inhibiting corneal neovascularization (CNV) from 91.6 ± 2.03% to 13.5 ± 1.87% in a rat model of CNV. This study contributes to engineering of protein NPs by using a facile strategy for overcoming the weaknesses of protein drugs and protein NPs, such as weak tissue barrier permeability, low encapsulation efficiency, poor loading capacity, and susceptibility to inactivation.
The vitamin A metabolite all-trans retinoic acid (RA) is critical for normal skin function. Ultraviolet irradiation (UV) markedly reduces the mRNA and protein of the two major nuclear retinoid receptors, RAR-.gamma. and RXR-.alpha. in human skin in vivo. One half the dose of UV that causes skin reddening was sufficient to reduce retinoid receptor mRNA levels. Maximal reduction of RAR-.gamma. and RXR-.alpha. proteins occurred between 8 and 16 hours after UV irradiation. With multiple exposures to UV, RXR-.alpha.  remained decreased, but RAR-.gamma. recovered to normal levels. Application of RA 24 hours before UV exposure partially prevented loss of nuclear retinoid receptors. UV irradiation completely prevented RA induction of two retinoid receptor-regulated genes, cellular retinoic acid binding protein-II(CRABP-II) and RA 4-hydroxylase. In contrast, UV irradiation did not affect 1,25-dihydroxyvitamin D3 induction of the vitamin D receptor-regulated gene, vitamin 0 24-hydroxylase, indicating that UV selectively interferes with the retinoid-signaling pathway. These data demonstrate for the first time that UV  specially reduces retinoid receptor levels and dramatically suppresses retinoid-responsive gene expression in human skin in vivo. In effect, UV  causes a functional vitamin A deficiency that could have deleterious effects on skin function, contributing to skin photoaging and carcinogenesis, which can be ameliorated by application of a retinoid prior to exposure.
FIELD: medicine. ^ SUBSTANCE: invention relates to medicine, namely to hematology and cardiology. Method includes administration to patients of complex from hypocaloric diet, dosed static and dynamic physical activity, including morning hygienic gymnastics, preventive medical gymnastics, divided physical exercise throughout the day, daily swimming for not less than 30 min per day in the middle of the day, intake of lisinopril in dose 10 mg 1 time per day in the morning and simvastatin 20 mg 1 time per day in the morning during 2 months. Combined application of all components makes it possible to reduce SEA in patients with AH with AO and D, reducing it to the level close to such for healthy people, during 2 months of treatment. ^ EFFECT: reduction of spontaneous erythrocyte aggregation (SEA) in case of arterial hypertension (AH) with abdominal obesity (AO) and dyslipidemia (D). ^ 2 ex
Coronary artery disease (CAD) poses a substantial threat to global health, leading to significant morbidity and mortality worldwide. It has a significant genetic component that has been studied through genome-wide association studies (GWAS) over the past 17 years. These studies have made progress with larger sample sizes, diverse ancestral backgrounds, and the discovery of multiple genomic regions related to CAD risk. In this review, we provide a comprehensive overview of CAD GWAS, including information about the genetic makeup of the disease and the importance of ethnic diversity in these studies. We also discuss challenges of identifying causal genes and variants within GWAS loci with a focus on non-coding regions. Additionally, we highlight tissues and cell types relevant to CAD, and discuss clinical implications of GWAS findings including polygenic risk scores, sex-specific differences in CAD genetics, ethnical aspects of personalized interventions, and GWAS guided drug development.
The invention provides a traditional Chinese medicine for treating pelvic inflammation of the urinary system and a preparation method thereof. The traditional Chinese medicine is prepared from the following raw materials, by weight, 1-8 parts of mantis egg-case, 1-5 parts of polygala root, 1-5 parts of calamus, 5-10 parts of keel, 1-3 parts of ginseng, 1-5 parts of Poria cocos, 3-6 parts of Chinese angelica and 3-5 parts of tortoise plastron. The traditional Chinese medicine mainly treats unpalpable intense abdominal pain with abdominal distension, fever, shiver, nausea and vomiting even persistent vomiting, dry stool or diarrhea, deep-colored urine, yellow viscous leucorrhea, red tongue and deficiency of both heart and kidney. The kidney stores the essence and governs storage. If storage governing fails due to kidney, dysfunction of urinary bladder is caused so as to lead to frequent urination or enuresis. Deficiency of both heart and kidney leads to unsteady and perturbed mind and amnesia.
Endometriosis (EMs) is one of the common and frequently occurring diseases in women of childbearing age, which seriously affects the health and quality of life of the vast majority of women. The pathogenesis of endometriosis is unknown until now, and the recurrence rate of existing treatment methods is high. It is more and more necessary to introduce new therapeutic methods and strategies in view of the mechanism associated with the reduction of natural killer cell (NK) cytotoxicity. In this study, routine therapy combined with NK cell therapy was used in the treatment of severe endometriosis. The clinical data were collected to confirm the efficacy and safety of NK cell therapy. It is expected to provide a new way of thinking and method for the clinical treatment of EMs.
We will equip a cluster-randomized stepped-wedge trial design. We will select and onboard hospitals randomly from three districts in pre-intervention period which eventually go into post-intervention period. The study will be conducted in three phases. The pre-intervention period for eight weeks for baseline data collection. Then intervention period (introduce thermal jackets) for another 24 weeks, and post-intervention period for endline data collection for eight weeks. In the control phase, all the eligible neonates enrolled in the hospitals whose parents agree to participate in the study will be observed and monitored for their thermal status (euthermia, hypothermia, and hyperthermia). Once the hospitals shift to case phase the eligible neonates will be given with thermal jacket. The icddr,b team will observe and monitor the enrolled neonates' thermal status throughout the event period. For this study, the definition of an event is the data from an individual enrolled infant on six hours' basis. Thus, every twenty-four hours, we can collect four events from a single neonate. During thermal care uptake, let it be with KMC or thermal jacket, the axillary temperature of the enrolled neonates will be recorded every 60 minutes. Feeding history will be recorded until discharge. According to the national newborn health SOP, during both control and case phases, mothers will be encouraged to provide KMC. The thermal jacket will be offered to mother when KMC will be ceased or not given by the neonate's family members. The thermal jacket intervention will be ceased for each neonate if mother wants to provide KMC or doesn't wish to put the neonate on the thermal jacket anymore. Thermal jacket will be provided for the time period as long as mother or legal guardian wishes to keep their neonate in the jacket without any time limitation. Mothers or caregivers of each neonate will be provided with training on KMC and thermal jacket and due support during the uptake of the KMC and thermal jacket will be provided as well. The data those will be collected during the pre-phase will be the control data and data that will be collected during the post-phase will be the intervention data.
Platelets are a major component of clot formation which can lead to thrombotic events. Antiplatelet agents have been found to reduce cardiovascular events in different clinical settings. The commonest agent that has been used is aspirin which works by inhibiting the cyclooxygenase pathway within the platelet and consequently preventing the release of tromboxane A2. A second group of agents called thienopyridines can inhibit platelets by blocking the P2Y12 receptor. Clopidogrel (Plavix) is currently a widely used thienopyridine that has been used for the treatment of patients presenting with the acute coronary syndrome and patients undergoing percutaneous coronary angioplasty (PCI). Antiplatelet therapy has reduced the occurrence of thrombotic events following PCI, including myocardial infarction and stent thrombosis. However, despite dual therapy with aspirin and clopidogrel, a significant number of patients continue to experience cardiovascular events. There is a now growing body of evidence that recurrence of ischemic complications may be attributed to poor response to clopidogrel and that persistence of enhanced platelet reactivity despite the use of clopidogrel is believed to be clinically relevant.1 The mechanisms leading to poor clopidogrel effects are not fully explained.

Our pilot study will use the VerifyNow device as an ex vivo method to measure platelet inhibition in patients treated with clopidogrel in the setting of STEMI. Since July 2004, the standard of care at the University of Ottawa Heart Institute for the treatment of STEMI has been primary PCI in which all patients receive aspirin 160 mg po either in the field or on arrival in the emergency department and clopidogrel 600 mg po given on arrival to the hospital. Little is known of the pharmacokinetics of clopidogrel in the setting of STEMI. Clopidogrel must be absorbed and activated by the liver to be effective. The physiological mechanisms for these steps may be greatly disturbed in patients presenting with STEMI. Therefore, the purpose of this study will be to examine the degree of platelet inhibition at various time points in this select patient population using the current 600 mg dose of clopidogrel and comparing this dose to other doses of clopidogrel to determine the optimal loading dose in the context of STEMI.
Motivational interviewing is a client-centered, directive method for enhancing intrinsic motivation to change by exploring and resolving ambivalence (Miller \& Rollnick. 1993). This 45 minutes individual motivational intervention focuses on risky injection practices.
BACKGROUND/AIMS: Osteosarcoma is a prevalent and aggressive primary malignant bone tumor affecting children and adolescents. Despite advancements in sequencing technologies, there remains a lack of reliable prognostic biomarkers and effective targeted therapies for osteosarcoma. This study focuses on identifying key prognostic genes, particularly the role of GNAS, in osteosarcoma progression.
METHODS: Bioinformatics analyses were performed on osteosarcoma datasets from the Gene Expression Omnibus (GEO). Differential gene expression analysis, weighted correlation network analysis (WGCNA), and survival analysis identified potential prognostic hub genes. The expression and function of these genes were validated through immunohistochemistry and animal experiments. Specifically, the role of GNAS was investigated through siRNA-mediated knockdown in osteosarcoma cell lines and nude mice models.
RESULTS: Five hub genes (PROP1, GNAS, CYP4F2, LHX3, CNGB1) were identified as significantly related to osteosarcoma prognosis. Among these, GNAS was found to be highly expressed in osteosarcoma tissues compared to normal tissues. Immunohistochemical analysis confirmed the elevated expression of GNAS in osteosarcoma samples. GNAS mutation analysis revealed a low mutation rate in osteosarcoma, suggesting its oncogenic role is independent of mutational status. Animal experiments demonstrated that knocking down GNAS significantly inhibited tumor growth and induced apoptosis in osteosarcoma cells.
CONCLUSION: GNAS is highly expressed in osteosarcoma and associated with poor prognosis, acting as an oncogene in osteosarcoma progression. Targeting GNAS could be a potential therapeutic strategy for osteosarcoma. Further studies on GNAS-related signaling pathways may provide deeper insights into the molecular mechanisms driving osteosarcoma malignancy.
This group will receive routine clinical care and act as the control group for the primary objective: To compare the mean daily dose of UVR (SEDs) reaching the face between the intervention group and control group over a 3 week period in June to July (follow-up 1). This group will receive the intervention in 2019, to allow within group change to be assessed.
Enhanced Couples Group: consists of eight 90-minute sessions, conducted weekly. ECG has a didactic educational content presented by the group leader or practice of specific relationship communication, relationship support, and couple-focused stress management. ECG participants are also given instruction about what types of behaviors are unsupportive and training in how to not behave in an unsupportive manner.
The utility model discloses an operation system using laser heat for treating fundus diseases. The operation system comprises a gold nanorod, a treatment laser source, a fundus imaging system and a PC control platform. The treatment laser source comprises a semiconductor laser unit, an adapter, a spectroscope, a power meter and a slit-lamp microscope. Light spot adjustment on near-infrared lasers emitted by the semiconductor laser unit is carried out through the adapter, and power detection is carried out by the power meter through the spectroscope. Fundus structure observation is carried out by the slit-lamp microscope through the spectroscope. The fundus imaging system comprises a fundus camera, a confocal laser scanning funduscope, an optical coherence chromatography imager and a photo-acoustic imager, and forms a multi-modal and multi-function imaging system.
Venlafaxine will not be administered. They will be evaluated only at baseline (T0).
In a double-blind, placebo-controlled study of 32 patients of both sexes, aged 32 to 69 years, with stable angina, propranolol 100 mg t.i.d. was administered for 4 weeks and shown to be more effective than placebo in reducing the rate of angina episodes and in prolonging total exercise time.

Twelve male patients with moderately severe angina pectoris were studied in a double-blind, crossover study. Patients were randomized to either propranolol hydrochloride extended-release capsules 160 mg daily or conventional propranolol 40 mg four times a day for 2 weeks. 

Nitroglycerine tablets were allowed during the study. Blood pressure, heart rate and ECG’s were recorded during serial exercise treadmill testing. Propranolol hydrochloride extended-release capsules were as effective as conventional propranolol for exercise heart rate, systolic and diastolic blood pressure, duration of anginal pain and ST-segment depression before or after exercise, exercise duration, angina attack rate and nitroglycerine consumption.

In another double-blind, randomized, crossover trial, the effectiveness of propranolol hydrochloride extended-release capsules 160 mg daily and conventional propranolol 40 mg four times a day were evaluated in 13 patients with angina. ECG’s were recorded while patients exercised until angina developed. Propranolol hydrochloride extended-release capsules were as effective as conventional propranolol for amount of exercise performed, ST-segment depression, number of anginal attacks, amount of nitroglycerine consumed, systolic and diastolic blood pressures and heart rate at rest and after exercise.
A method for producing foams, such as sponges, from hydrocolloids is described. A solid or semi-solid gel is formed by dissolving polymeric material in an aqueous solvent. The gel formed is allowed to set, and may optionally then be cut into the desired shape. The gel may be frozen to allow formation of ice crystals to act as porogens. Subsequently, the gel is exposed to a radiant energy field for drying under vacuum. This causes the solvent to boil and the foam or sponge is formed. Medicinally active ingredients may be included in the process, so that the sponge or foam formed contains the active ingredient dispersed within the structure. The method described provides an alternative to the conventional methods of particulate leaching or freeze drying.